心瑋醫療-B(6609.HK)暫錄155億港元孖展 超購136倍
格隆匯8月12日丨神經介入器械公司心瑋醫療-B(6609.HK)目前正處於招股期(8月10日-8月13日)。數據顯示,截至今日10點,心瑋醫療暫錄得孖展總額約155.28億港元,錄得超購136倍。本次心瑋醫療發行660.18萬股,其中10%為公開發售,90%為國際發售,另有15%超額配股權。每股發行價160-171港元,每手50股,預期於8月20日上市。據悉,心瑋醫療當前已形成了包括缺血性腦卒中取栓治療、缺血性腦卒中狹窄治療、出血性腦卒中治療、心源性腦卒中預防、血管通路產品等五大產品線。其中,Captor及左心耳(LAA)封堵器則為其兩款核心產品,Captor現已在中國商業化,左心耳(LAA)封堵器預計將於今年四季度取得NMPA批文,並於2022年二季度開始銷售。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.